Lixte Biotechnology Holdings Discounted Cash Flow

As of the most recent data, LIXT shows a DCF fair value of $0.092. Scroll down for historical charts and peer comparison views.

Lixte Biotechnology Holdings's DCF reading of $0.092 (98.7% overvalued) is a model output, not a certainty. Small changes in long-term growth or the discount rate can move fair value a lot. Treat the number as a structured starting point, then verify whether Lixte Biotechnology Holdings's recent cash-flow history supports the assumptions.

Besides this discounted cash flow page, Stockcircle has Lixte Biotechnology Holdings's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect DCF fair value (currently $0.092) with ownership activity and broader fundamentals.

Lixte Biotechnology Holdings's DCF fair value is $0.092; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.